MedTrace Logo

Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression

NCT00176020 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2006-03-15

No results posted yet for this study

Summary

The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be:

* Treatment A: 500 mg nicotinic acid (Niacor(R))
* Treatment B: Niacor(R) Placebo

Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.

Conditions

  • Healthy

Interventions

DRUG

nicotinic acid

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Gerd Mikus, MD Bsc · Department Internal Medicine VI

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176020 on ClinicalTrials.gov